Skip Navigation
Skip to contents

JPTM : Journal of Pathology and Translational Medicine

OPEN ACCESS
SEARCH
Search

Search

Page Path
HOME > Search
28 "Survival"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
A clinicopathologic and immunohistochemical study of primary and secondary breast angiosarcoma
Evi Abada, Hyejeong Jang, Seongho Kim, Rouba Ali-Fehmi, Sudeshna Bandyopadhyay
J Pathol Transl Med. 2022;56(6):342-353.   Published online October 27, 2022
DOI: https://doi.org/10.4132/jptm.2022.08.31
  • 714 View
  • 67 Download
AbstractAbstract PDFSupplementary Material
Background
We aimed to study the clinicopathologic and immunohistochemical (IHC) (CD117, c-Myc, and p53) characteristics, and overall survival of primary and secondary breast angiosarcoma (BAS).
Methods
This was a retrospective study of BAS cases diagnosed between 1997 and 2020 at our institution. Hematoxylin and eosin-stained slides were reviewed for tumor morphology, margin status, and lymph node metastasis. CD117, p53, D2-40, CD31, and c-Myc IHC stains were performed on 11 viable tissue blocks. Additional clinical information was obtained from the electronic medical records.
Results
Seventeen patients with BAS were identified. Of these, five (29%) were primary and 12 (71%) were secondary BAS, respectively. The median age at diagnosis for primary BAS was 36 years. The median age at diagnosis for secondary BAS was 67 years. The median time to secondary BAS development following radiotherapy was 6.5 years (range, 2 to 12 years). There was no significant difference between primary and secondary BAS in several histopathologic parameters examined, including histologic grade, necrosis, mitotic count, lymph node metastasis, and positive tumor margins. There was also no difference in CD117, p53, D2-40, CD31, and c-Myc expression by IHC between primary and secondary BAS. During a median followup of 21 months, primary BAS had two (40%) reported deaths and secondary BAS had three (25%) reported deaths. However, this difference in survival between both groups was not statistically significant (hazard ratio, 0.51; 95% confidence interval, 0.09 to 3.28; p = .450).
Conclusions
BAS is a rare and aggressive disease. No histologic, IHC (CD117, c-Myc, and p53), or survival differences were identified between primary and secondary BAS in this study.
Clinicopathologic features and survival outcomes of ocular melanoma: a series of 31 cases from a tertiary university hospital
Selin Kestel, Feriha Pınar Uyar Göçün, Betül Öğüt, Özlem Erdem
J Pathol Transl Med. 2022;56(4):187-198.   Published online May 3, 2022
DOI: https://doi.org/10.4132/jptm.2022.03.10
  • 2,368 View
  • 144 Download
  • 1 Citations
AbstractAbstract PDFSupplementary Material
Background
We aimed to determine the effect of clinicopathologic features on overall survival among Caucasian ocular melanoma patients in the Central Anatolia region of Turkey.
Methods
This single-center study included conjunctival (n = 12) and uveal (n = 19) melanoma patients diagnosed between January 2008 and March 2020. Clinicopathologic features and outcomes were reviewed retrospectively. Five cases were tested for BRAF V600 mutations with real-time polymerase chain reaction, and one case was tested with nextgeneration sequencing. Survival was calculated using the Kaplan-Meier method.
Results
Thirty-one patients had a mean initial age of 58.32 years (median, 61 years; range 25 to 78 years). There were 13 male and 18 female patients. The median follow-up time was 43.5 months (range, 6 to 155 months) for conjunctival melanoma and 35 months (range, 8 to 151 months) for uveal melanoma. When this study ended, eight of the 12 conjunctival melanoma patients (66.7%) and nine of the 19 uveal melanoma patients (47.4%) had died. The presence of tumor-infiltrating lymphocytes was related to improved overall survival in conjunctival melanoma (p = .014), whereas the presence of ulceration (p = .030), lymphovascular invasion (p = .051), tumor in the left eye (p = .012), tumor thickness of > 2 mm (p = .012), and mitotic count of >1/mm² (p = .012) reduced the overall survival in conjunctival melanoma. Uveal melanoma tumors with the largest diameter of 9.1–15 mm led to the lowest overall survival among subgroups (p = .035). Involvement of the conjunctiva (p=.005) and lens (p = .003) diminished overall survival in uveal melanoma. BRAF V600 mutation was present in one case of conjunctival melanoma, GNAQ R183Q mutation was present in one case of uveal melanoma. Patients with uveal melanoma presented with an advanced pathological tumor stage compared to those with conjunctival melanoma (p = .019).
Conclusions
This study confirmed the presence of tumor-infiltrating lymphocytes as a favorable factor in conjunctival melanoma and conjunctival and lens involvement as unfavorable prognostic factors in uveal melanoma for overall survival, respectively.

Citations

Citations to this article as recorded by  
  • Metastatic melanoma: clinicopathologic features and overall survival comparison
    Selin Kestel, Feriha Pınar Uyar Göçün, Betül Öğüt, Özlem Erdem
    Acta Dermatovenerologica Alpina Pannonica et Adriatica.2022;[Epub]     CrossRef
Immunohistochemical expression of programmed death-ligand 1 and CD8 in glioblastomas
Dina Mohamed El Samman, Manal Mohamed El Mahdy, Hala Sobhy Cousha, Zeinab Abd El Rahman Kamar, Khaled Abdel Karim Mohamed, Hoda Hassan Abou Gabal
J Pathol Transl Med. 2021;55(6):388-397.   Published online October 14, 2021
DOI: https://doi.org/10.4132/jptm.2021.08.04
  • 2,035 View
  • 117 Download
  • 1 Citations
AbstractAbstract PDF
Background
Glioblastoma is the most aggressive primary malignant brain tumor in adults and is characterized by poor prognosis. Immune evasion occurs via programmed death-ligand 1 (PD-L1)/programmed death receptor 1 (PD-1) interaction. Some malignant tumors have responded to PD-L1/PD-1 blockade treatment strategies, and PD-L1 has been described as a potential predictive biomarker. This study discussed the expression of PD-L1 and CD8 in glioblastomas.
Methods
Thirty cases of glioblastoma were stained immunohistochemically for PD-L1 and CD8, where PD-L1 expression in glioblastoma tumor tissue above 1% is considered positive and CD-8 is expressed in tumor infiltrating lymphocytes. The expression of each marker was correlated with clinicopathologic parameters. Survival analysis was conducted to correlate progression-free survival (PFS) and overall survival (OS) with PD-L1 and CD8 expression.
Results
Diffuse/fibrillary PD-L1 was expressed in all cases (mean expression, 57.6%), whereas membranous PD-L1 was expressed in six of 30 cases. CD8-positive tumor-infiltrating lymphocytes (CD8+ TILs) had a median expression of 10%. PD-L1 and CD8 were positively correlated (p = .001). High PD-L1 expression was associated with worse PFS and OS (p = .026 and p = .001, respectively). Correlation of CD8+ TILs percentage with age, sex, tumor site, laterality, and outcomes were statistically insignificant. Multivariate analysis revealed that PD-L1 was the only independent factor that affected prognosis.
Conclusions
PD-L1 expression in patients with glioblastoma is robust; higher PD-L1 expression is associated with lower CD8+ TIL expression and worse prognosis.

Citations

Citations to this article as recorded by  
  • Analysis of PD-L1 and CD3 Expression in Glioblastoma Patients and Correlation with Outcome: A Single Center Report
    Navid Sobhani, Victoria Bouchè, Giovanni Aldegheri, Andrea Rocca, Alberto D’Angelo, Fabiola Giudici, Cristina Bottin, Carmine Antonio Donofrio, Maurizio Pinamonti, Benvenuto Ferrari, Stefano Panni, Marika Cominetti, Jahard Aliaga, Marco Ungari, Antonio Fi
    Biomedicines.2023; 11(2): 311.     CrossRef
The Prognostic Impact of Synchronous Ipsilateral Multiple Breast Cancer: Survival Outcomes according to the Eighth American Joint Committee on Cancer Staging and Molecular Subtype
Jinah Chu, Hyunsik Bae, Youjeong Seo, Soo Youn Cho, Seok-Hyung Kim, Eun Yoon Cho
J Pathol Transl Med. 2018;52(6):396-403.   Published online October 23, 2018
DOI: https://doi.org/10.4132/jptm.2018.10.03
  • 4,681 View
  • 83 Download
  • 6 Citations
AbstractAbstract PDF
Background
In the current American Joint Committee on Cancer staging system of breast cancer, only tumor size determines T-category regardless of whether the tumor is single or multiple. This study evaluated if tumor multiplicity has prognostic value and can be used to subclassify breast cancer.
Methods
We included 5,758 patients with invasive breast cancer who underwent surgery at Samsung Medical Center, Seoul, Korea, from 1995 to 2012.
Results
Patients were divided into two groups according to multiplicity (single, n = 4,744; multiple, n = 1,014). Statistically significant differences in lymph node involvement and lymphatic invasion were found between the two groups (p < .001). Patients with multiple masses tended to have luminal A molecular subtype (p < .001). On Kaplan-Meier survival analysis, patients with multiple masses had significantly poorer disease-free survival (DFS) (p = .016). The prognostic significance of multiplicity was seen in patients with anatomic staging group I and prognostic staging group IA (p = .019 and p = .032, respectively). When targeting patients with T1-2 N0 M0, hormone receptor–positive, and human epidermal growth factor receptor 2 (HER2)–negative cancer, Kaplan-Meier survival analysis also revealed significantly reduced DFS with multiple cancer (p = .031). The multivariate analysis indicated that multiplicity was independently correlated with worse DFS (hazard ratio, 1.23; 95% confidence interval, 1.03 to 1.47; p = .025). The results of this study indicate that tumor multiplicity is frequently found in luminal A subtype, is associated with frequent lymph node metastasis, and is correlated with worse DFS.
Conclusions
Tumor multiplicity has prognostic value and could be used to subclassify invasive breast cancer at early stages. Adjuvant chemotherapy would be necessary for multiple masses of T1–2 N0 M0, hormone-receptor-positive, and HER2-negative cancer.

Citations

Citations to this article as recorded by  
  • Deep learning-based system for automatic prediction of triple-negative breast cancer from ultrasound images
    Alexandre Boulenger, Yanwen Luo, Chenhui Zhang, Chenyang Zhao, Yuanjing Gao, Mengsu Xiao, Qingli Zhu, Jie Tang
    Medical & Biological Engineering & Computing.2023; 61(2): 567.     CrossRef
  • Multicentre prospective cohort study of unmet supportive care needs among patients with breast cancer throughout their cancer treatment trajectory in Penang: a PenBCNeeds Study protocol
    Noorsuzana Mohd Shariff, Nizuwan Azman, Rohayu Hami, Noor Mastura Mohd Mujar, Mohammad Farris Iman Leong Bin Abdullah
    BMJ Open.2021; 11(3): e044746.     CrossRef
  • The subgross morphology of breast carcinomas: a single-institution series of 2033 consecutive cases documented in large-format histology slides
    Tibor Tot, Maria Gere, Syster Hofmeyer, Annette Bauer, Ulrika Pellas
    Virchows Archiv.2020; 476(3): 373.     CrossRef
  • Editorial for “Synchronous Breast Cancer: Phenotypic Similarities on MRI”
    Uma Sharma
    Journal of Magnetic Resonance Imaging.2020; 52(1): 309.     CrossRef
  • Synchronous Multiple Breast Cancers—Do We Need to Reshape Staging?
    Minodora Onisâi, Adrian Dumitru, Iuliana Iordan, Cătălin Aliuș, Oana Teodor, Adrian Alexandru, Daniela Gheorghiță, Iulian Antoniac, Adriana Nica, Alexandra-Ana Mihăilescu, Sebastian Grădinaru
    Medicina.2020; 56(5): 230.     CrossRef
  • Molecular mechanism of triple‑negative breast cancer‑associated BRCA1 and the identification of signaling pathways
    Feng Qi, Wen‑Xing Qin, Yuan‑Sheng Zang
    Oncology Letters.2019;[Epub]     CrossRef
Extramural Perineural Invasion in pT3 and pT4 Gastric Carcinomas
Alejandro España-Ferrufino, Leonardo S. Lino-Silva, Rosa A. Salcedo-Hernández
J Pathol Transl Med. 2018;52(2):79-84.   Published online November 9, 2017
DOI: https://doi.org/10.4132/jptm.2017.11.01
  • 6,326 View
  • 128 Download
  • 5 Citations
AbstractAbstract PDF
Background
Perineural invasion (PNI) is widely studied in malignant tumors, and its prognostic significance is well demonstrated. Most studies have focused on evaluating the mural PNI (mPNI); however, extramural PNI (ePNI) may influence the prognosis in gastric cancer. We evaluated the prognostic value of ePNI compared with mPNI in gastric cancer in this observational comparative cross-sectional study.
Methods
Seventy-three pT3 and pT4 gastric carcinomas with PNI were evaluated. Forty-eight (65.7%) were in the mPNI group and the remaining in the ePNI group.
Results
Clinicopathologic characteristics between the two groups were similar, except for the outcomes. The 5-year disease-specific survival (DSS) rate was 64% for the mPNI group and 50% for the ePNI group (p=.039), a difference that did not remain significant in multivariate analysis. The only independent adverse prognostic factor in multivariate analysis was the presence of lymph node metastasis (hazard ratio, 1.757; 95% confidence interval, 1.082 to 2.854; p=.023).
Conclusions
We demonstrated the prognostic effect of ePNI for DSS in surgically resected pT3–pT4 gastric cancer patients. ePNI could be considered in the staging and prognostic systems of gastric cancer to stratify patients with a high risk of recurrence.

Citations

Citations to this article as recorded by  
  • Targeting tumor innervation: premises, promises, and challenges
    Xinyu Li, Xueqiang Peng, Shuo Yang, Shibo Wei, Qing Fan, Jingang Liu, Liang Yang, Hangyu Li
    Cell Death Discovery.2022;[Epub]     CrossRef
  • Cancer-Associated Neurogenesis and Nerve-Cancer Cross-talk
    Deborah A. Silverman, Vena K. Martinez, Patrick M. Dougherty, Jeffrey N. Myers, George A. Calin, Moran Amit
    Cancer Research.2021; 81(6): 1431.     CrossRef
  • Perineural Invasion and Postoperative Adjuvant Chemotherapy Efficacy in Patients With Gastric Cancer
    Qing Tao, Wen Zhu, Xiaohui Zhao, Mei Li, Yongqian Shu, Deqiang Wang, Xiaoqin Li
    Frontiers in Oncology.2020;[Epub]     CrossRef
  • Perineural invasion as a predictive factor for survival outcome in gastric cancer patients: a systematic review and meta-analysis
    Bochao Zhao, Wu Lv, Di Mei, Rui Luo, Shiyang Bao, Baojun Huang, Jie Lin
    Journal of Clinical Pathology.2020; 73(9): 544.     CrossRef
  • Consensus-Expressed CXCL8 and MMP9 Identified by Meta-Analyzed Perineural Invasion Gene Signature in Gastric Cancer Microarray Data
    Xiuzhi Jia, Minjia Lu, Chen Rui, Ying Xiao
    Frontiers in Genetics.2019;[Epub]     CrossRef
Loss of Progesterone Receptor Expression Is an Early Tumorigenesis Event Associated with Tumor Progression and Shorter Survival in Pancreatic Neuroendocrine Tumor Patients
Sung Joo Kim, Soyeon An, Jae Hoon Lee, Joo Young Kim, Ki-Byung Song, Dae Wook Hwang, Song Cheol Kim, Eunsil Yu, Seung-Mo Hong
J Pathol Transl Med. 2017;51(4):388-395.   Published online June 8, 2017
DOI: https://doi.org/10.4132/jptm.2017.03.19
  • 5,765 View
  • 123 Download
  • 12 Citations
AbstractAbstract PDF
Background
Pancreatic neuroendocrine tumors (PanNETs) are the second most common pancreatic neoplasms and there is no well-elucidated biomarker to stratify their detection and prognosis. Previous studies have reported that progesterone receptor (PR) expression status was associated with poorer survival in PanNET patients.
Methods
To validate previous studies, PR protein expression was assessed in 21 neuroendocrine microadenomas and 277 PanNETs and compared with clinicopathologic factors including patient survival.
Results
PR expression was gradually decreased from normal islets (49/49 cases, 100%) to neuroendocrine microadenoma (14/21, 66.6%) to PanNETs (60/277, 21.3%; p < .001). PanNETs with loss of PR expression were associated with increased tumor size (p < .001), World Health Organization grade (p = .001), pT classification (p < .001), perineural invasion (p = .028), lymph node metastasis (p = .004), activation of alternative lengthening of telomeres (p = .005), other peptide hormonal expression (p < .001) and ATRX/DAXX expression (p = .015). PanNET patients with loss of PR expression (5-year survival rate, 64.1%) had significantly poorer recurrence-free survival outcomes than those with intact PR expression (90%) by univariate (p = .012) but not multivariate analyses. Similarly, PanNET patients with PR expression loss (5-year survival rate, 76%) had significantly poorer overall survival by univariate (p = .015) but not multivariate analyses.
Conclusions
Loss of PR expression was noted in neuroendocrine microadenomas and was observed in the majority of PanNETs. This was associated with increased grade, tumor size, and advanced pT and pN classification; and was correlated with decreased patient survival time by univariate but not multivariate analyses. Loss of PR expression can provide additional information on shorter disease-free survival in PanNET patients.

Citations

Citations to this article as recorded by  
  • Combined Infiltrative Macroscopic Growth Pattern and Infiltrative Microscopic Tumor Border Status Is a Novel Surrogate Marker of Poor Prognosis in Patients With Pancreatic Neuroendocrine Tumor
    Bokyung Ahn, Joo Young Kim, Seung-Mo Hong
    Archives of Pathology & Laboratory Medicine.2023; 147(1): 100.     CrossRef
  • Diagnostic and Prognostic Impact of Progesterone Receptor Immunohistochemistry: A Study Evaluating More Than 16,000 Tumors
    Florian Viehweger, Lisa-Marie Tinger, David Dum, Natalia Gorbokon, Anne Menz, Ria Uhlig, Franziska Büscheck, Andreas M. Luebke, Claudia Hube-Magg, Andrea Hinsch, Doris Höflmayer, Christoph Fraune, Patrick Lebok, Sören Weidemann, Maximilian Lennartz, Frank
    Analytical Cellular Pathology.2022; 2022: 1.     CrossRef
  • Venous invasion and lymphatic invasion are correlated with the postoperative prognosis of pancreatic neuroendocrine neoplasm
    Sho Kiritani, Junichi Arita, Yuichiro Mihara, Rihito Nagata, Akihiko Ichida, Yoshikuni Kawaguchi, Takeaki Ishizawa, Nobuhisa Akamatsu, Junichi Kaneko, Kiyoshi Hasegawa
    Surgery.2022;[Epub]     CrossRef
  • Prognostic Nomograms to Predict Overall Survival and Cancer-Specific Survival of Patients With Pancreatic Neuroendocrine Tumors
    Zuoli Song, Sumei Wang, Yujing Wu, Jinjuan Zhang, Shuye Liu
    Pancreas.2021; 50(3): 414.     CrossRef
  • Pancreatic High-Grade Neuroendocrine Neoplasms in the Korean Population: A Multicenter Study
    Haeryoung Kim, Soyeon An, Kyoungbun Lee, Sangjeong Ahn, Do Youn Park, Jo-Heon Kim, Dong-Wook Kang, Min-Ju Kim, Mee Soo Chang, Eun Sun Jung, Joon Mee Kim, Yoon Jung Choi, So-Young Jin, Hee Kyung Chang, Mee-Yon Cho, Yun Kyung Kang, Myunghee Kang, Soomin Ahn
    Cancer Research and Treatment.2020; 52(1): 263.     CrossRef
  • Systemic distribution of progesterone receptor subtypes in human tissues
    Teeranut Asavasupreechar, Ryoko Saito, Yasuhiro Miki, Dean P. Edwards, Viroj Boonyaratanakornkit, Hironobu Sasano
    The Journal of Steroid Biochemistry and Molecular Biology.2020; 199: 105599.     CrossRef
  • Progesteron receptor expression in insulin producing cells of neuroendocrine neoplasms
    Tomoyoshi Tachibana, Atsuko Kasajima, Takeshi Aoki, Tomoaki Tabata, Keely McNamara, Samaneh Yazdani, Sato Satoko, Fumiyoshi Fujishima, Fuyuhiko Motoi, Michiaki Unno, Hironobu Sasano
    The Journal of Steroid Biochemistry and Molecular Biology.2020; 201: 105694.     CrossRef
  • Prognostic and predictive factors on overall survival and surgical outcomes in pancreatic neuroendocrine tumors: recent advances and controversies
    Lingaku Lee, Tetsuhide Ito, Robert T Jensen
    Expert Review of Anticancer Therapy.2019; 19(12): 1029.     CrossRef
  • Immunohistochemistry, carcinomas of unknown primary, and incidence rates
    Edward B. Stelow, Hadi Yaziji
    Seminars in Diagnostic Pathology.2018; 35(2): 143.     CrossRef
  • Carbonic anhydrase 9 expression in well-differentiated pancreatic neuroendocrine neoplasms might be associated with aggressive behavior and poor survival
    Joo Young Kim, Sang Hwa Lee, Soyeon An, Sung Joo Kim, You-Na Sung, Ki-Byung Song, Dae Wook Hwang, Song Cheol Kim, Seung-Mo Hong
    Virchows Archiv.2018; 472(5): 739.     CrossRef
  • Prognostic value of progesterone receptor in solid pseudopapillary neoplasm of the pancreas: evaluation of a pooled case series
    Feiyang Wang, Zibo Meng, Shoukang Li, Yushun Zhang, Heshui Wu
    BMC Gastroenterology.2018;[Epub]     CrossRef
  • Estrogens modulate progesterone receptor expression and may contribute to progesterone-mediated apoptotic β-cell death
    Viviane Abreu Nunes
    Endocrinology&Metabolism International Journal.2018;[Epub]     CrossRef
Size of Non-lepidic Invasive Pattern Predicts Recurrence in Pulmonary Mucinous Adenocarcinoma: Morphologic Analysis of 188 Resected Cases with Reappraisal of Invasion Criteria
Soohyun Hwang, Joungho Han, Misun Choi, Myung-Ju Ahn, Yong Soo Choi
J Pathol Transl Med. 2017;51(1):56-68.   Published online October 16, 2016
DOI: https://doi.org/10.4132/jptm.2016.09.17
  • 8,174 View
  • 204 Download
  • 3 Citations
AbstractAbstract PDF
Background
We reviewed a series of 188 resected pulmonary mucinous adenocarcinomas (MAs) to clarify the prognostic significance of lepidic and non-lepidic patterns.
Methods
Non-lepidic patterns were divided into bland, non-distorted acini with uncertain invasiveness (pattern 1), unequivocal invasion into stroma (pattern 2), or invasion into alveolar spaces (pattern 3).
Results
The mean proportion of invasive patterns (patterns 2 and 3) was lowest in small (≤ 3 cm) tumors, and gradually increased in intermediate (> 3 cm and ≤ 7 cm) and large (> 7 cm) tumors (8.4%, 34.3%, and 50.1%, respectively). Adjusted T (aT) stage, as determined by the size of invasive patterns, was positively correlated with adverse histologic and clinical features including older age, male sex, and ever smokers. aTis tumors, which were exclusively composed of lepidic pattern (n = 9), or a mixture of lepidic and pattern 1 (n = 40) without any invasive patterns, showed 100% disease- free survival (DFS). The aT1mi tumors, with minimal (≤ 5 mm) invasive patterns (n = 63), showed a 95.2% 5-year DFS, with recurrences (n = 2) limited to tumors greater than 3 cm in total size (n = 23). Both T and aT stage were significantly associated with DFS; however, survival within the separate T-stage subgroups was stratified according to the aT stage, most notably in the intermediatestage subgroups. In multivariate analysis, the size of invasive patterns (p = .020), pleural invasion (p < .001), and vascular invasion (p = .048) were independent predictors of recurrence, whereas total size failed to achieve statistical significance (p = .121).
Conclusions
This study provides a rationale for histologic risk stratification in pulmonary MA based on the extent of invasive growth patterns with refined criteria for invasion.

Citations

Citations to this article as recorded by  
  • Radiological and clinical features of screening-detected pulmonary invasive mucinous adenocarcinoma
    Dae Hyeon Kim, So Young Bae, Kwon Joong Na, Samina Park, In Kyu Park, Chang Hyun Kang, Young Tae Kim
    Interactive CardioVascular and Thoracic Surgery.2022; 34(2): 229.     CrossRef
  • Optimal method for measuring invasive size that predicts survival in invasive mucinous adenocarcinoma of the lung
    Tomonari Oki, Keiju Aokage, Shogo Nomura, Kenta Tane, Tomohiro Miyoshi, Norihiko Shiiya, Kazuhito Funai, Masahiro Tsuboi, Genichiro Ishii
    Journal of Cancer Research and Clinical Oncology.2020; 146(5): 1291.     CrossRef
  • Prognostic Impact of Histopathologic Features in Pulmonary Invasive Mucinous Adenocarcinomas
    Wei-Chin Chang, Yu Zhi Zhang, Eric Lim, Andrew G Nicholson
    American Journal of Clinical Pathology.2020; 154(1): 88.     CrossRef
Usual Interstitial Pneumonia with Lung Cancer: Clinicopathological Analysis of 43 Cases
Dae Hyun Song, In Ho Choi, Sang Yun Ha, Kang Min Han, Jae Jun Lee, Min Eui Hong, Kyeongman Jeon, Man Pyo Chung, Jhingook Kim, Joungho Han
Korean J Pathol. 2014;48(1):10-16.   Published online February 25, 2014
DOI: https://doi.org/10.4132/KoreanJPathol.2014.48.1.10
  • 8,232 View
  • 67 Download
  • 14 Citations
AbstractAbstract PDF
Background

Previous studies have suggested an association between usual interstitial pneumonia (UIP) and lung cancer (Ca). However, clinical and histological information is not enough to determine such an association, due to the low incidence and short survival time of patients with both conditions.

Methods

We retrospectively reviewed the clinical and histological records of Ca patients with UIP between January 1999 and August 2013 at the Samsung Medical Center, Seoul, Korea. We found 43 patients who had Ca with UIP (UIP-Ca). Previously reported data of eighty-four patients with UIP-only were included as a comparison group.

Results

Smoking is related to poor prognosis in patients with UIP-Ca, and the number of patients with a high smoking index of more than 30 pack-years significantly increased in UIP-Ca patients compared with UIP-only patients. There is no significant prognostic differentiation between UIP-Ca patients and UIP-only patients. Microscopically, UIP-Ca patients showed characteristically heterogeneous histological patterns and degrees of differentiation. There were many foci of squamous metaplasia or dysplasia at the peripheral area of squamous cell carcinomas.

Conclusions

We report 43 cases of UIP-Ca. Our results suggest that smoking is related to cancer occurrence in UIP patients and poor prognosis in UIP-Ca patients.

Citations

Citations to this article as recorded by  
  • Prognosis of idiopathic pulmonary fibrosis without anti-fibrotic therapy: a systematic review
    Yet H. Khor, Yvonne Ng, Hayley Barnes, Nicole S.L. Goh, Christine F. McDonald, Anne E. Holland
    European Respiratory Review.2020; 29(157): 190158.     CrossRef
  • Linfoma difuso de células B grandes pulmonar en paciente con neumonía intersticial no específica
    Luis Gorospe Sarasúa, Paola Arrieta, Anabelle Chinea-Rodríguez, Carlos de la Puente-Bujidos
    Reumatología Clínica.2019; 15(6): e151.     CrossRef
  • Diffuse Large B-cell Lymphoma of the Lung in a Patient With Nonspecific Interstitial Pneumonia
    Luis Gorospe Sarasúa, Paola Arrieta, Anabelle Chinea-Rodríguez, Carlos de la Puente-Bujidos
    Reumatología Clínica (English Edition).2019; 15(6): e151.     CrossRef
  • Characteristics of lung cancer among patients with idiopathic pulmonary fibrosis and interstitial lung disease – analysis of institutional and population data
    Joo Heung Yoon, Mehdi Nouraie, Xiaoping Chen, Richard H Zou, Jacobo Sellares, Kristen L Veraldi, Jared Chiarchiaro, Kathleen Lindell, David O Wilson, Naftali Kaminski, Timothy Burns, Humberto Trejo Bittar, Samuel Yousem, Kevin Gibson, Daniel J Kass
    Respiratory Research.2018;[Epub]     CrossRef
  • Genomic profiles of lung cancer associated with idiopathic pulmonary fibrosis
    Ji An Hwang, Deokhoon Kim, Sung-Min Chun, SooHyun Bae, Joon Seon Song, Mi Young Kim, Hyun Jung Koo, Jin Woo Song, Woo Sung Kim, Jae Cheol Lee, Hyeong Ryul Kim, Chang-Min Choi, Se Jin Jang
    The Journal of Pathology.2018; 244(1): 25.     CrossRef
  • Survival after repeated surgery for lung cancer with idiopathic pulmonary fibrosis: a retrospective study
    Seijiro Sato, Yuki Shimizu, Tatsuya Goto, Akihiko Kitahara, Terumoto Koike, Hiroyuki Ishikawa, Takehiro Watanabe, Masanori Tsuchida
    BMC Pulmonary Medicine.2018;[Epub]     CrossRef
  • Alveolar Squamous Cell Metaplasia: Preneoplastic Lesion?
    Adriana Handra-Luca
    Journal of Pathology and Translational Medicine.2018; 52(6): 355.     CrossRef
  • Low expression of long noncoding RNA CDKN2B-AS1 in patients with idiopathic pulmonary fibrosis predicts lung cancer by regulating the p53-signaling pathway
    Yufeng Du, Xiaoyan Hao, Xuejun Liu
    Oncology Letters.2018;[Epub]     CrossRef
  • A clinicopathological study of surgically resected lung cancer in patients with usual interstitial pneumonia
    Yasutaka Watanabe, Yoshinori Kawabata, Nobuyuki Koyama, Tomohiko Ikeya, Eishin Hoshi, Noboru Takayanagi, Shinichiro Koyama
    Respiratory Medicine.2017; 129: 158.     CrossRef
  • Risk of the preoperative underestimation of tumour size of lung cancer in patients with idiopathic interstitial pneumonias
    Mariko Fukui, Kazuya Takamochi, Takeshi Matsunaga, Shiaki Oh, Katsutoshi Ando, Kazuhiro Suzuki, Atsushi Arakawa, Toshimasa Uekusa, Kenji Suzuki
    European Journal of Cardio-Thoracic Surgery.2016; 50(3): 428.     CrossRef
  • The Idiopathic Interstitial Pneumonias: Histology and Imaging
    Diane C. Strollo, Teri J. Franks, Jeffrey R. Galvin
    Seminars in Roentgenology.2015; 50(1): 8.     CrossRef
  • Do Chest Expansion Exercises Aid Re-shaping the Diaphragm Within the First 72 Hours Following Lung Transplantation in a Usual Interstitial Pneumonia Patient?
    Massimiliano Polastri, Erika Venturini, Saverio Pastore, Andrea Dell'Amore
    Physiotherapy Research International.2015; 20(3): 191.     CrossRef
  • Scrotal wall metastasis from a primary lung adenocarcinoma
    Marie-Louise M. Coussa-Koniski, Pia A. Maalouf, Nehme E. Raad, Noha A. Bejjani
    Respiratory Medicine Case Reports.2015; 15: 77.     CrossRef
  • The Ratio KL-6 to SLX in Serum for Prediction of the Occurrence of Drug-Induced Interstitial Lung Disease in Lung Cancer Patients with Idiopathic Interstitial Pneumonias Receiving Chemotherapy
    Kosuke Kashiwabara, Hiroshi Semba, Shinji Fujii, Shinsuke Tsumura, Ryota Aoki
    Cancer Investigation.2015; 33(10): 516.     CrossRef
Prognostic Significance of BCL9 Expression in Hepatocellular Carcinoma
Jiyeon Hyeon, Soomin Ahn, Jae Jun Lee, Dae Hyun Song, Cheol-Keun Park
Korean J Pathol. 2013;47(2):130-136.   Published online April 24, 2013
DOI: https://doi.org/10.4132/KoreanJPathol.2013.47.2.130
  • 6,763 View
  • 51 Download
  • 17 Citations
AbstractAbstract PDF
Background

BCL9 enhances β-catenin-mediated transcriptional activity regardless of the mutational status of the Wnt signaling components and increases the cell proliferation, migration, invasion, and metastatic potential of tumor cells. The goal of this study was to elucidate the prognostic significance of BCL9 protein expression in hepatocellular carcinoma (HCC) patients.

Methods

We evaluated BCL9 protein expression by immunohistochemistry in tumor tissue from 288 primary HCC patients who underwent curative hepatectomy. The impact of BCL9 expression on the survival of the patients was analyzed. The median follow-up period was 97.1 months.

Results

Nuclear BCL9 protein expression was observed in 74 (25.7%) of the 288 HCCs. BCL9 expression was significantly associated with younger age (p=0.038), higher Edmondson grade (p=0.001), microvascular invasion (p=0.013), and intrahepatic metastasis (p=0.017). Based on univariate analyses, BCL9 expression showed an unfavorable influence on both disease-free survival (DFS, p=0.012) and disease-specific survival (DSS, p=0.032). Multivariate analyses revealed that higher Barcelona Clinic Liver Cancer stage was an independent predictor of both shorter DFS (p<0.001) and shorter DSS (p<0.001). BCL9 expression tended to be an independent predictor of shorter DFS (p=0.078).

Conclusions

BCL9 protein expression might be a marker of shorter DFS in HCC patients after curative hepatectomy.

Citations

Citations to this article as recorded by  
  • The role of BCL9 genetic variation as a biomarker for hepatitis C-related hepatocellular carcinoma in Egyptian patients
    Eman Abd El Razek Abbas, Ahmed Barakat Barakat, Mohamed Hassany, Samar Samir Youssef
    Journal of Genetic Engineering and Biotechnology.2022;[Epub]     CrossRef
  • Molecular Targets and Signaling Pathways of microRNA-122 in Hepatocellular Carcinoma
    Kwang-Hoon Chun
    Pharmaceutics.2022; 14(7): 1380.     CrossRef
  • Wnt/β-Catenin Signalling and Its Cofactor BCL9L Have an Oncogenic Effect in Bladder Cancer Cells
    Roland Kotolloshi, Mieczyslaw Gajda, Marc-Oliver Grimm, Daniel Steinbach
    International Journal of Molecular Sciences.2022; 23(10): 5319.     CrossRef
  • Bcl9 Depletion Modulates Endothelial Cell in Tumor Immune Microenvironment in Colorectal Cancer Tumor
    Zhuang Wei, Mei Feng, Zhongen Wu, Shuru Shen, Di Zhu
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Wnt Signaling Pathway Is among the Drivers of Liver Metastasis
    Ivana Samaržija
    Livers.2021; 1(4): 180.     CrossRef
  • Nuclear Expression of Pygo2 Correlates with Poorly Differentiated State Involving c-Myc, PCNA and Bcl9 in Myanmar Hepatocellular Carcinoma
    Myo Win Htun, Yasuaki Shibata, Kyaw Soe, Takehiko Koji
    ACTA HISTOCHEMICA ET CYTOCHEMICA.2021; 54(6): 195.     CrossRef
  • Wnt status-dependent oncogenic role of BCL9 and BCL9L in hepatocellular carcinoma
    Nicole Huge, Maria Sandbothe, Anna K. Schröder, Amelie Stalke, Marlies Eilers, Vera Schäffer, Brigitte Schlegelberger, Thomas Illig, Beate Vajen, Britta Skawran
    Hepatology International.2020; 14(3): 373.     CrossRef
  • Structure and function of Pygo in organ development dependent and independent Wnt signalling
    Yan Shi, Xiushan Wu, Shuoji Zhu, Huanlei Huang, Jian Zhuang, Haiyun Yuan, Wuzhou Yuan, Ping Zhu
    Biochemical Society Transactions.2020; 48(4): 1781.     CrossRef
  • BCL9/BCL9L in hepatocellular carcinoma: will it or Wnt it be the next therapeutic target?
    Akshata Moghe, Satdarshan P. Monga
    Hepatology International.2020; 14(4): 460.     CrossRef
  • Loss of BCL9/9l suppresses Wnt driven tumourigenesis in models that recapitulate human cancer
    David M. Gay, Rachel A. Ridgway, Miryam Müller, Michael C. Hodder, Ann Hedley, William Clark, Joshua D. Leach, Rene Jackstadt, Colin Nixon, David J. Huels, Andrew D. Campbell, Thomas G. Bird, Owen J. Sansom
    Nature Communications.2019;[Epub]     CrossRef
  • Immunohistochemical Mapping of Bcl9 Using Two Antibodies that Recognize Different Epitopes Is Useful to Characterize Juvenile Development of Hepatocellular Carcinoma in Myanmar
    Myat Thu Soe, Yasuaki Shibata, Myo Win Htun, Kuniko Abe, Kyaw Soe, Nay Win Than, Thann Lwin, Myat Phone Kyaw, Takehiko Koji
    ACTA HISTOCHEMICA ET CYTOCHEMICA.2019; 52(1): 9.     CrossRef
  • Low BCL9 expression inhibited ovarian epithelial malignant tumor progression by decreasing proliferation, migration, and increasing apoptosis to cancer cells
    Jing Wang, Mingjun Zheng, Liancheng Zhu, Lu Deng, Xiao Li, Linging Gao, Caixia Wang, Huimin Wang, Juanjuan Liu, Bei Lin
    Cancer Cell International.2019;[Epub]     CrossRef
  • SOX7 Suppresses Wnt Signaling by Disrupting β-Catenin/BCL9 Interaction
    Rong Fan, HaiYan He, Wang Yao, YanFeng Zhu, XunJie Zhou, MingTai Gui, Jing Lu, Hao Xi, ZhongLong Deng, Min Fan
    DNA and Cell Biology.2018; 37(2): 126.     CrossRef
  • Hypoxia activates Wnt/β-catenin signaling by regulating the expression of BCL9 in human hepatocellular carcinoma
    Wei Xu, Wang Zhou, Mo Cheng, Jing Wang, Zhian Liu, Shaohui He, Xiangji Luo, Wending Huang, Tianrui Chen, Wangjun Yan, Jianru Xiao
    Scientific Reports.2017;[Epub]     CrossRef
  • Hepatocellular carcinoma biology predicts survival outcome after liver transplantation in the USA
    Mohamed Abd El-Fattah
    Indian Journal of Gastroenterology.2017; 36(2): 117.     CrossRef
  • miR-30a acts as a tumor suppressor by double-targeting COX-2 and BCL9 in H. pylori gastric cancer models
    Xuan Liu, Qing Ji, Chengcheng Zhang, Xiaowei Liu, Yanna Liu, Ningning Liu, Hua Sui, Lihong Zhou, Songpo Wang, Qi Li
    Scientific Reports.2017;[Epub]     CrossRef
  • BCL9, a coactivator for Wnt/β-catenin transcription, is targeted by miR-30c and is associated with prostate cancer progression
    XIAO-HUI LING, ZHI-YUN CHEN, HONG-WEI LUO, ZE-ZHEN LIU, YING-KE LIANG, GUAN-XING CHEN, FU-NENG JIANG, WEI-DE ZHONG
    Oncology Letters.2016; 11(3): 2001.     CrossRef
CHD1L Is a Marker for Poor Prognosis of Hepatocellular Carcinoma after Surgical Resection
Jiyeon Hyeon, Soomin Ahn, Cheol-Keun Park
Korean J Pathol. 2013;47(1):9-15.   Published online February 25, 2013
DOI: https://doi.org/10.4132/KoreanJPathol.2013.47.1.9
  • 6,480 View
  • 51 Download
  • 19 Citations
AbstractAbstract PDF
Background

The gene for chromodomain helicase/ATPase DNA binding protein 1-like (CHD1L) was recently identified as a target oncogene within the 1q21 amplicon, which occurs in 46% to 86% of primary hepatocellular carcinoma (HCC) cases. However, the prognostic significance of CHD1L in HCC remains uncertain. In this study, we investigated the roles of CHD1L in the prognosis of HCC.

Methods

We investigated the expressions of CHD1L in tumor tissue microarrays of 281 primary HCC patients who underwent surgical resection using immunohistochemistry. Prognostic factors of HCC were examined by univariate and multivariate analyses. The median follow-up period was 75.6 months.

Results

CHD1L expression was observed in 48 of the 281 HCCs (17.1%). CHD1L expression was associated with a younger age (p=0.033), higher Edmondson grade (p=0.019), microvascular invasion (p<0.001), major portal vein invasion (p=0.037), higher American Joint Committee on Cancer T stage (p=0.001), lower albumin level (p=0.047), and higher α-fetoprotein level (p=0.002). Multivariate analyses revealed that CHD1L expression (p=0.027), Edmondson grade III (p=0.034), and higher Barcelona Clinic Liver Cancer stage (p<0.001) were independent predictors of shorter disease-free survival.

Conclusions

CHD1L expression might be a prognostic marker of shorter disease-free survival in HCC patients after surgical resection.

Citations

Citations to this article as recorded by  
  • Design, Synthesis, and Biological Evaluation of the First Inhibitors of Oncogenic CHD1L
    Brett J. Prigaro, Hector Esquer, Qiong Zhou, Laura A. Pike, Paul Awolade, Xin-He Lai, Adedoyin D. Abraham, Joshua M. Abbott, Brock Matter, Uday B. Kompella, Wells A. Messersmith, Daniel L. Gustafson, Daniel V. LaBarbera
    Journal of Medicinal Chemistry.2022; 65(5): 3943.     CrossRef
  • Diversity roles of CHD1L in normal cell function and tumorigenesis
    Xifeng Xiong, Xudong Lai, Aiguo Li, Zhihe Liu, Ningfang Ma
    Biomarker Research.2021;[Epub]     CrossRef
  • Elevated serum alpha-fetoprotein levels are associated with poor prognosis of hepatocellular carcinoma after surgical resection: A systematic review and meta-analysis
    Hong-Lin Chen, Yu-Hua Chen, Lin Du, Yi-Ping Song, Bin Zhu
    Arab Journal of Gastroenterology.2021; 22(1): 12.     CrossRef
  • Genome-wide scanning for CHD1L gene in papillary thyroid carcinoma complicated with type 2 diabetes mellitus
    Y. Y. Kang, J. J. Li, J. X. Sun, J. X. Wei, C. Ding, C. L. Shi, G. Wu, K. Li, Y. F. Ma, Y. Sun, H. Qiao
    Clinical and Translational Oncology.2021; 23(12): 2536.     CrossRef
  • The high expression of CHD1L and its clinical significance in human solid tumors
    Long Zhang, Yufen Jiang, Panpan Jiao, Xiaohong Deng, Yuancai Xie
    Medicine.2021; 100(10): e24851.     CrossRef
  • Clinical Significance of Trk Receptor Expression as a New Therapeutic Target in Hepatocellular Carcinoma
    Sangjoon Choi, Sujin Park, Yoon Ah Cho, Cheol-Keun Park, Sang Yun Ha
    Pathology & Oncology Research.2020; 26(4): 2587.     CrossRef
  • Hepatocyte ploidy and pathological mutations in hepatocellular carcinoma: impact on oncogenesis and therapeutics
    Taiji Yamazoe, Taizo Mori, Sachiyo Yoshio, Tatsuya Kanto
    Global Health & Medicine.2020; 2(5): 273.     CrossRef
  • First-in-Class Inhibitors of Oncogenic CHD1L with Preclinical Activity against Colorectal Cancer
    Joshua M. Abbott, Qiong Zhou, Hector Esquer, Laura Pike, Travis P. Broneske, Sébastien Rinaldetti, Adedoyin D. Abraham, Dominique A. Ramirez, Paul J. Lunghofer, Todd M. Pitts, Daniel P. Regan, Aik Choon Tan, Daniel L. Gustafson, Wells A. Messersmith, Dani
    Molecular Cancer Therapeutics.2020; 19(8): 1598.     CrossRef
  • Prognostic role of chromodomain helicase DNA binding protein 1-like protein in human solid cancers
    Wanwei Liu, Jiwei Xu, Caiyun Zhang
    Medicine.2018; 97(29): e11522.     CrossRef
  • CHD1L Expression Increases Tumor Progression and Acts as a Predictive Biomarker for Poor Prognosis in Pancreatic Cancer
    Chuan Liu, Xiaowei Fu, Zhiwei Zhong, Jing Zhang, Haiyan Mou, Qiong Wu, Tianle Sheng, Bo Huang, Yeqing Zou
    Digestive Diseases and Sciences.2017; 62(9): 2376.     CrossRef
  • Overexpression of CHD1L is associated with poor survival and aggressive tumor biology in esophageal carcinoma
    Ze-Han Liu, Qi Zhang, Yi-Jie Ding, Ying-Hui Ren, Hui-Peng Yang, Qing Xi, Ying-Nan Cheng, Guo-Lin Miao, Hong-Kun Liu, Cai-Xia Li, Wen-Qiang Yan, Yan Li, Zhenyi Xue, Lijuan Zhang, Xin-Ye Li, Chen-Long Zhao, Yurong Da, Xian-Zhong Wu, Jun-Qiang Chen, Rongxin
    Oncotarget.2017; 8(43): 74178.     CrossRef
  • CHD1L Regulates Cell Cycle, Apoptosis, and Migration in Glioma
    Jie Sun, Li Zhang, Hongyu Zhao, Xiaojun Qiu, Wenjuan Chen, Donglin Wang, Na Ban, Shaochen Fan, Chaoyan Shen, Xiaojie Xia, Bin Ji, Yuchan Wang
    Cellular and Molecular Neurobiology.2016; 36(4): 565.     CrossRef
  • Expression of DBC1 is associated with poor prognosis in hepatitis virus-related hepatocellular carcinoma
    Sang Yun Ha, Jeong Hoon Kim, Jung Wook Yang, Hyunsik Bae, Hae Yon Cho, Cheol-Keun Park
    Pathology - Research and Practice.2016; 212(7): 616.     CrossRef
  • The Overexpression of CCAR1 in Hepatocellular Carcinoma Associates with Poor Prognosis
    Sang Yun Ha, Jeong Hoon Kim, Jung Wook Yang, Jimin Kim, Binnari Kim, Cheol-Keun Park
    Cancer Research and Treatment.2016; 48(3): 1065.     CrossRef
  • Genetic alterations in hepatocellular carcinoma: An update
    Zhao-Shan Niu, Xiao-Jun Niu, Wen-Hong Wang
    World Journal of Gastroenterology.2016; 22(41): 9069.     CrossRef
  • CHD1L is a novel independent prognostic factor for gastric cancer
    Z. Su, J. Zhao, G. Xian, W. Geng, Z. Rong, Y. Wu, C. Qin
    Clinical and Translational Oncology.2014; 16(8): 702.     CrossRef
  • Presence of CHD1L Over-Expression Is Associated with Aggressive Tumor Biology and Is a Novel Prognostic Biomarker for Patient Survival in Human Breast Cancer
    Jiayi Wu, Yu Zong, Xiaochun Fei, Xiaosong Chen, Ou Huang, Jianrong He, Weiguo Chen, Yafen Li, Kunwei Shen, Li Zhu, Xin-Yuan Guan
    PLoS ONE.2014; 9(8): e98673.     CrossRef
  • CHD1L: a novel oncogene
    Wen Cheng, Yun Su, Feng Xu
    Molecular Cancer.2013; 12(1): 170.     CrossRef
  • Expression of CHD1L in bladder cancer and its influence on prognosis and survival
    Feng Tian, Feng Xu, Zheng-Yu Zhang, Jing-Ping Ge, Zhi-Feng Wei, Xiao-Feng Xu, Wen Cheng
    Tumor Biology.2013; 34(6): 3687.     CrossRef
Microsatellite Instability Status in Gastric Cancer: A Reappraisal of Its Clinical Significance and Relationship with Mucin Phenotypes
Joo-Yeun Kim, Na Ri Shin, Ahrong Kim, Hyun-Jeong Lee, Won-young Park, Jee-Yeon Kim, Chang-Hun Lee, Gi-Young Huh, Do Youn Park
Korean J Pathol. 2013;47(1):28-35.   Published online February 25, 2013
DOI: https://doi.org/10.4132/KoreanJPathol.2013.47.1.28
  • 7,723 View
  • 87 Download
  • 54 Citations
AbstractAbstract PDF
Background

Gastric cancers with microsatellite instabilities (MSI) have been reported to be associated with favorable prognosis. However, the significance of the effect of MSI on the clinicopathological features, as well as its association with mucin phenotype, remains unclear.

Methods

MSI status was assessed in 414 cases of gastric cancer using polymerase chain reaction analysis of five microsatellite loci, as recommended by National Cancer Institution criteria. The expression of mucins (MUC5AC, MUC6, MUC2, and CD10) was assessed.

Results

Out of 414 total cases of gastric cancer, 380 (91.7%), 11 (2.7%), and 23 (5.6%) were microsatellite stable (MSS), low-level MSI (MSI-L), and high-level MSI (MSI-H), respectively. Compared to MSS/MSI-L, MSI-H gastric cancers were associated with older age (p=0.010), tumor size (p=0.014), excavated gross (p=0.042), intestinal type (p=0.028), aggressive behaviors (increase of T stage [p=0.009]), perineural invasion [p=0.022], and lymphovascular emboli [p=0.027]). MSI-H gastric cancers were associated with tumor necrosis (p=0.041), tumor-infiltrating lymphocytes (≥2/high power field, p<0.001), expanding growth patterns (p=0.038), gastric predominant mucin phenotypes (p=0.028), and MUC6 expression (p=0.016). Tumor necrosis (≥10% of mass, p=0.031), tumor-infiltrating lymphocytes (p<0.001), intestinal type (p=0.014), and gastric mucin phenotypes (p=0.020) could represent independent features associated with MSI-H gastric cancers. MSI-H intestinal type gastric cancers had a tendency for poor prognosis in univariate analysis (p=0.054) but no association in Cox multivariate analysis (p=0.197).

Conclusions

Our data suggest that MSI-H gastric cancers exhibit distinct aggressive biologic behaviors and a gastric mucin phenotype. This contradicts previous reports that describe MSI-H gastric cancer as being associated with favorable prognosis.

Citations

Citations to this article as recorded by  
  • Deep learning captures selective features for discrimination of microsatellite instability from pathologic tissue slides of gastric cancer
    Sung Hak Lee, Yujin Lee, Hyun‐Jong Jang
    International Journal of Cancer.2023; 152(2): 298.     CrossRef
  • Genomic and Immunologic Markers of Intrinsic Resistance to Pembrolizumab Monotherapy in Microsatellite Instability-High Gastric Cancer: Observations from a Prospective Phase II Study
    Haibo Qiu
    Global Medical Genetics.2022; 09(02): 060.     CrossRef
  • Clinicopathological features of PD-L1 protein expression, EBV positivity, and MSI status in patients with advanced gastric and esophagogastric junction adenocarcinoma in Japan
    Tsutomu Yoshida, Go Ogura, Mikiko Tanabe, Takuo Hayashi, Chiho Ohbayashi, Mizutomo Azuma, Chikara Kunisaki, Yoichi Akazawa, Soji Ozawa, Sohei Matsumoto, Takayoshi Suzuki, Akira Mitoro, Tetsu Fukunaga, Akiko Shimizu, Go Fujimoto, Takashi Yao
    Cancer Biology & Therapy.2022; 23(1): 191.     CrossRef
  • Development of Tissue-Agnostic Treatments for Patients with Cancer
    Steven Lemery, Lola Fashoyin-Aje, Leigh Marcus, Sandra Casak, Julie Schneider, Marc Theoret, Paul Kluetz, Richard Pazdur, Julia A. Beaver
    Annual Review of Cancer Biology.2022; 6(1): 147.     CrossRef
  • A multicenter study on the preoperative prediction of gastric cancer microsatellite instability status based on computed tomography radiomics
    Xiuqun Liang, Yinbo Wu, Ying Liu, Danping Yu, Chencui Huang, Zhi Li
    Abdominal Radiology.2022; 47(6): 2036.     CrossRef
  • Combination of AKT1 and CDH1 mutations predicts primary resistance to immunotherapy in dMMR/MSI-H gastrointestinal cancer
    Zhenghang Wang, Qi Zhang, Changsong Qi, Yuezong Bai, Feilong Zhao, Hui Chen, Zhongwu Li, Xicheng Wang, Mifen Chen, Jifang Gong, Zhi Peng, Xiaotian Zhang, Jinping Cai, Shiqing Chen, Xiaochen Zhao, Lin Shen, Jian Li
    Journal for ImmunoTherapy of Cancer.2022; 10(6): e004703.     CrossRef
  • Eldest gastric cancer patient with high microsatellite instability responding to pembrolizumab
    Akinobu Wakasugi, Akinori Sasaki, Risa Okamoto, Yasuaki Motomura
    International Cancer Conference Journal.2022; 12(1): 59.     CrossRef
  • Baseline lesion number as an efficacy predictive and independent prognostic factor and its joint utility with TMB for PD-1 inhibitor treatment in advanced gastric cancer
    Xiao-Li Wei, Jian-Ying Xu, De-Shen Wang, Dong-Liang Chen, Chao Ren, Jia-Ning Li, Feng Wang, Feng-Hua Wang, Rui-Hua Xu
    Therapeutic Advances in Medical Oncology.2021; 13: 175883592198899.     CrossRef
  • Clinical and morphological portrait of tumors with microsatellite instability
    A. A. Musaelyan, V. D. Nazarov, A. S. Budnikova, S. V. Lapin, S. L. Vorobyev, V. L. Emanuel, A. A. Zakharenko, S. V. Orlov
    Advances in Molecular Oncology.2021; 8(2): 52.     CrossRef
  • How to Best Exploit Immunotherapeutics in Advanced Gastric Cancer: Between Biomarkers and Novel Cell-Based Approaches
    Michele Ghidini, Angelica Petrillo, Andrea Botticelli, Dario Trapani, Alessandro Parisi, Anna La Salvia, Elham Sajjadi, Roberto Piciotti, Nicola Fusco, Shelize Khakoo
    Journal of Clinical Medicine.2021; 10(7): 1412.     CrossRef
  • Microsatellite instability in Gastric Cancer: Between lights and shadows
    Elisabetta Puliga, Simona Corso, Filippo Pietrantonio, Silvia Giordano
    Cancer Treatment Reviews.2021; 95: 102175.     CrossRef
  • Impact of microsatellite status on negative lymph node count and prognostic relevance after curative gastrectomy
    Zhenghao Cai, Junjun Ma, Shuchun Li, Abe Fingerhut, Jing Sun, Lu Zang, Chao Yan, Wentao Liu, Zhenggang Zhu, Minhua Zheng
    Journal of Surgical Oncology.2021;[Epub]     CrossRef
  • A greater lymph node yield is required during pathological examination in microsatellite instability-high gastric cancer
    Zhenghao Cai, Haiqin Song, Abe Fingerhut, Jing Sun, Junjun Ma, Luyang Zhang, Shuchun Li, Chaoran Yu, Minhua Zheng, Lu Zang
    BMC Cancer.2021;[Epub]     CrossRef
  • Determinants of Response and Intrinsic Resistance to PD-1 Blockade in Microsatellite Instability–High Gastric Cancer
    Minsuk Kwon, Minae An, Samuel J. Klempner, Hyuk Lee, Kyoung-Mee Kim, Jason K. Sa, Hee Jin Cho, Jung Yong Hong, Taehyang Lee, Yang Won Min, Tae Jun Kim, Byung-Hoon Min, Woong-Yang Park, Won Ki Kang, Kyu-Tae Kim, Seung Tae Kim, Jeeyun Lee
    Cancer Discovery.2021; 11(9): 2168.     CrossRef
  • Advanced Gastric Cancer: Current Treatment Landscape and a Future Outlook for Sequential and Personalized Guide: Swiss Expert Statement Article
    Alexander R. Siebenhüner, Sara De Dosso, Daniel Helbling, Christoforos Astaras, Petr Szturz, Peter Moosmann, Stefanie Pederiva, Thomas Winder, Philippe Von Burg, Markus Borner
    Oncology Research and Treatment.2021; 44(9): 485.     CrossRef
  • High homogeneity of mismatch repair deficiency in advanced prostate cancer
    Christoph Fraune, Ronald Simon, Doris Höflmayer, Katharina Möller, David Dum, Franziska Büscheck, Claudia Hube-Magg, Georgia Makrypidi-Fraune, Martina Kluth, Andrea Hinsch, Eike Burandt, Till Sebastian Clauditz, Waldemar Wilczak, Guido Sauter, Stefan Steu
    Virchows Archiv.2020; 476(5): 745.     CrossRef
  • High homogeneity of MMR deficiency in ovarian cancer
    Christoph Fraune, Janina Rosebrock, Ronald Simon, Claudia Hube-Magg, Georgia Makrypidi-Fraune, Martina Kluth, Franziska Büscheck, Doris Höflmayer, Barbara Schmalfeldt, Volkmar Müller, Linn Wölber, Isabell Witzel, Peter Paluchowski, Christian Wilke, Uwe He
    Gynecologic Oncology.2020; 156(3): 669.     CrossRef
  • Molecular Classification of Gastric Cancer among Alaska Native People
    Holly Martinson, Dominic Mallari, Christine Richter, Tsung-Teh Wu, James Tiesinga, Steven Alberts, Matthew Olnes
    Cancers.2020; 12(1): 198.     CrossRef
  • Tumor immune response and immunotherapy in gastric cancer
    Yoonjin Kwak, An Na Seo, Hee Eun Lee, Hye Seung Lee
    Journal of Pathology and Translational Medicine.2020; 54(1): 20.     CrossRef
  • MMR deficiency in urothelial carcinoma of the bladder presents with temporal and spatial homogeneity throughout the tumor mass
    Christoph Fraune, Ronald Simon, Claudia Hube-Magg, Georgia Makrypidi-Fraune, Christian Kähler, Martina Kluth, Doris Höflmayer, Franziska Büscheck, David Dum, Andreas M. Luebke, Eike Burandt, Till Sebastian Clauditz, Waldemar Wilczak, Guido Sauter, Stefan
    Urologic Oncology: Seminars and Original Investigations.2020; 38(5): 488.     CrossRef
  • MMR Deficiency is Homogeneous in Pancreatic Carcinoma and Associated with High Density of Cd8-Positive Lymphocytes
    Christoph Fraune, Eike Burandt, Ronald Simon, Claudia Hube-Magg, Georgia Makrypidi-Fraune, Martina Kluth, Franziska Büscheck, Doris Höflmayer, Niclas Ch. Blessin, Tim Mandelkow, Wenchao Li, Daniel Perez, Jakob R. Izbicki, Waldemar Wilczak, Guido Sauter, J
    Annals of Surgical Oncology.2020; 27(10): 3997.     CrossRef
  • CD73's Potential as an Immunotherapy Target in Gastrointestinal Cancers
    Jerry B. Harvey, Luan H. Phan, Oscar E. Villarreal, Jessica L. Bowser
    Frontiers in Immunology.2020;[Epub]     CrossRef
  • Tumor copy-number alterations predict response to immune-checkpoint-blockade in gastrointestinal cancer
    Zhihao Lu, Huan Chen, Shuang Li, Jifang Gong, Jian Li, Jianling Zou, Lihong Wu, Jianing Yu, Wenbo Han, Huaibo Sun, Xi Jiao, Xiaotian Zhang, Zhi Peng, Ming Lu, Zhenghang Wang, Henghui Zhang, Lin Shen
    Journal for ImmunoTherapy of Cancer.2020; 8(2): e000374.     CrossRef
  • Protein expression-based classification of gastric cancer by immunohistochemistry of tissue microarray
    Chong Zhao, Zhiqiang Feng, Hongzhen He, Dan Zang, Hong Du, Hongli Huang, Yanlei Du, Jie He, Yongjian Zhou, Yuqiang Nie, Girijesh Kumar Patel
    PLOS ONE.2020; 15(10): e0238836.     CrossRef
  • Clinicopathologic Characteristics and Long-Term Outcome of Gastric Cancer Patients with Family History: Seven-Year Follow-Up Study for Korean Health Check-Up Subjects
    Jooyoung Lee, Su Jin Chung, Ji Min Choi, Yoo Min Han, Joo Sung Kim, Greger Lindberg
    Gastroenterology Research and Practice.2020; 2020: 1.     CrossRef
  • Implication of expression of MMR proteins and clinicopathological characteristics in gastric cancer
    Renu Verma, Puja Sakhuja, Ritu Srivastava, Prakash Chand Sharma
    Asia-Pacific Journal of Oncology.2020; : 1.     CrossRef
  • Prognostic significance of microsatellite‐instability in gastric and gastroesophageal junction cancer patients undergoing neoadjuvant chemotherapy
    Georg Martin Haag, Elena Czink, Aysel Ahadova, Thomas Schmidt, Leila Sisic, Susanne Blank, Ulrike Heger, Leonidas Apostolidis, Anne Katrin Berger, Christoph Springfeld, Felix Lasitschka, Dirk Jäger, Magnus Knebel Doeberitz, Matthias Kloor
    International Journal of Cancer.2019; 144(7): 1697.     CrossRef
  • Serological Markers Associated With Response to Immune Checkpoint Blockade in Metastatic Gastrointestinal Tract Cancer
    Zhihao Lu, Jianling Zou, Ying Hu, Shuang Li, Tao Zhou, Jifang Gong, Jian Li, Xiaotian Zhang, Jun Zhou, Ming Lu, Xicheng Wang, Zhi Peng, Changsong Qi, Yanyan Li, Jie Li, Yan Li, Jianyin Zou, Xiao Du, Henghui Zhang, Lin Shen
    JAMA Network Open.2019; 2(7): e197621.     CrossRef
  • Assessing molecular subtypes of gastric cancer: microsatellite unstable and Epstein-Barr virus subtypes. Methods for detection and clinical and pathological implications
    Carolina Martinez-Ciarpaglini, Tania Fleitas-Kanonnikoff, Valentina Gambardella, Marta Llorca, Cristina Mongort, Regina Mengual, Gema Nieto, Lara Navarro, Marisol Huerta, Susana Rosello, Desamparados Roda, Noelia Tarazona, Samuel Navarro, Gloria Ribas, An
    ESMO Open.2019; 4(3): e000470.     CrossRef
  • The role of pembrolizumab in the treatment of PD-L1 expressing gastric and gastroesophageal junction adenocarcinoma
    Gagandeep Brar, Manish A. Shah
    Therapeutic Advances in Gastroenterology.2019; 12: 175628481986976.     CrossRef
  • Novel Biomarkers for Prediction of Response to Preoperative Systemic Therapies in Gastric Cancer
    Alessandro Cavaliere, Valeria Merz, Simona Casalino, Camilla Zecchetto, Francesca Simionato, Hayley Louise Salt, Serena Contarelli, Raffaela Santoro, Davide Melisi
    Journal of Gastric Cancer.2019; 19(4): 375.     CrossRef
  • MICROSATELLITE INSTABILITY AND GASTRIC CARCINOMA. REVIEW OF THELITERATURE
    D. L. Rotin, O. V. Paklina, I. O. Tin’kova, D. N. Grekov
    Russian Journal of Biotherapy.2019; 18(4): 17.     CrossRef
  • Meta-analysis of microsatellite instability in relation to clinicopathological characteristics and overall survival in gastric cancer
    K Polom, L Marano, D Marrelli, R De Luca, G Roviello, V Savelli, P Tan, F Roviello
    British Journal of Surgery.2018; 105(3): 159.     CrossRef
  • Gastric poorly cohesive carcinoma: a correlative study of mutational signatures and prognostic significance based on histopathological subtypes
    Chae H Kwon, Young K Kim, Sojeong Lee, Ahrong Kim, Hye J Park, Yuri Choi, Yeo J Won, Do Y Park, Gregory Y Lauwers
    Histopathology.2018; 72(4): 556.     CrossRef
  • Microsatellite instability in gastric cancer: molecular bases, clinical perspectives, and new treatment approaches
    Margherita Ratti, Andrea Lampis, Jens C. Hahne, Rodolfo Passalacqua, Nicola Valeri
    Cellular and Molecular Life Sciences.2018; 75(22): 4151.     CrossRef
  • High-throughput Protein and mRNA Expression–based Classification of Gastric Cancers Can Identify Clinically Distinct Subtypes, Concordant With Recent Molecular Classifications
    Sangjeong Ahn, So-Jeong Lee, Yonugkeum Kim, Ahrong Kim, Nari Shin, Kyung Un Choi, Chang-Hun Lee, Gi Yeong Huh, Kyong-Mee Kim, Namrata Setia, Gregory Y. Lauwers, Do Youn Park
    American Journal of Surgical Pathology.2017; 41(1): 106.     CrossRef
  • Molecular Testing for Gastrointestinal Cancer
    Hye Seung Lee, Woo Ho Kim, Yoonjin Kwak, Jiwon Koh, Jeong Mo Bae, Kyoung-Mee Kim, Mee Soo Chang, Hye Seung Han, Joon Mee Kim, Hwal Woong Kim, Hee Kyung Chang, Young Hee Choi, Ji Y. Park, Mi Jin Gu, Min Jin Lhee, Jung Yeon Kim, Hee Sung Kim, Mee-Yon Cho
    Journal of Pathology and Translational Medicine.2017; 51(2): 103.     CrossRef
  • Molecular testing of gastrointestinal tumours
    Matthew Evans, Matthew Smith, Brendan O'Sullivan, Philippe Taniere
    Diagnostic Histopathology.2017; 23(10): 442.     CrossRef
  • Gastric Carcinomas With Lymphoid Stroma
    Raul S Gonzalez, Justin M M Cates, Frank Revetta, Loralee A McMahon, Kay Washington
    American Journal of Clinical Pathology.2017; 148(6): 477.     CrossRef
  • Meta-Analysis of Prognostic Role of Ki-67 Labeling Index in Gastric Carcinoma
    Jung-Soo Pyo, Nae Yu Kim
    The International Journal of Biological Markers.2017; 32(4): 447.     CrossRef
  • Tissue-Agnostic Drug Development
    Keith T. Flaherty, Dung T. Le, Steven Lemery
    American Society of Clinical Oncology Educational Book.2017; (37): 222.     CrossRef
  • Programmed death ligand-1 and MET co-expression is a poor prognostic factor in gastric cancers after resection
    Mi Jung Kwon, Kab-Choong Kim, Eun Sook Nam, Seong Jin Cho, Hye-Rim Park, Soo Kee Min, Jinwon Seo, Ji-Young Choe, Hye Kyung Lee, Ho Suk Kang, Kyueng-Whan Min
    Oncotarget.2017; 8(47): 82399.     CrossRef
  • Hypermutation and microsatellite instability in gastrointestinal cancers
    Kizuki Yuza, Masayuki Nagahashi, Satoshi Watanabe, Kazuaki Takabe, Toshifumi Wakai
    Oncotarget.2017; 8(67): 112103.     CrossRef
  • The emerging role of immunotherapy in gastric and esophageal adenocarcinoma
    Bruno Bockorny, Eirini Pectasides
    Future Oncology.2016; 12(15): 1833.     CrossRef
  • Expression of Mismatch Repair Proteins in Early and Advanced Gastric Cancer in Poland
    Katarzyna Karpińska-Kaczmarczyk, Magdalena Lewandowska, Małgorzata Ławniczak, Andrzej Białek, Elżbieta Urasińska
    Medical Science Monitor.2016; 22: 2886.     CrossRef
  • Immunotherapy for Gastroesophageal Cancer
    Emily Goode, Elizabeth Smyth
    Journal of Clinical Medicine.2016; 5(10): 84.     CrossRef
  • Lauren classification and individualized chemotherapy in gastric cancer
    JUNLI MA, HONG SHEN, LINDA KAPESA, SHAN ZENG
    Oncology Letters.2016; 11(5): 2959.     CrossRef
  • High-risk and low-risk gastric cancer areas in Italy and its association with microsatellite instability
    Karol Polom, Daniele Marrelli, Valeria Pascale, Giandomenico Roviello, Costantino Voglino, Henry Rho, Carla Vindigni, Mario Marini, Raffaele Macchiarelli, Franco Roviello
    Journal of Cancer Research and Clinical Oncology.2016; 142(8): 1817.     CrossRef
  • MUC2 Expression Is Correlated with Tumor Differentiation and Inhibits Tumor Invasion in Gastric Carcinomas: A Systematic Review and Meta-analysis
    Jung-Soo Pyo, Jin Hee Sohn, Guhyun Kang, Dong-Hoon Kim, Kyungeun Kim, In-Gu Do, Dong Hyun Kim
    Journal of Pathology and Translational Medicine.2015; 49(3): 249.     CrossRef
  • Correlation between microsatellite instability-high phenotype and occult lymph node metastasis in gastric carcinoma
    Jiwoon Choi, Soo Kyung Nam, Do Joong Park, Hwal Woong Kim, Hyung-Ho Kim, Woo Ho Kim, Hye Seung Lee
    APMIS.2015; 123(3): 215.     CrossRef
  • Clinicopathologic and molecular features associated with patient age in gastric cancer
    Ji Yeon Seo, Eun Hyo Jin, Hyun Jin Jo, Hyuk Yoon, Cheol Min Shin, Young Soo Park, Nayoung Kim, Hyun Chae Jung, Dong Ho Lee
    World Journal of Gastroenterology.2015; 21(22): 6905.     CrossRef
  • Molecular classification of gastric cancer: Towards a pathway-driven targeted therapy
    Ismael Riquelme, Kathleen Saavedra, Jaime A. Espinoza, Helga Weber, Patricia García, Bruno Nervi, Marcelo Garrido, Alejandro H. Corvalán, Juan Carlos Roa, Carolina Bizama
    Oncotarget.2015; 6(28): 24750.     CrossRef
  • A phylogenetic model for understanding the effect of gene duplication on cancer progression
    Qin Ma, Jaxk H. Reeves, David A. Liberles, Lili Yu, Zheng Chang, Jing Zhao, Juan Cui, Ying Xu, Liang Liu
    Nucleic Acids Research.2014; 42(5): 2870.     CrossRef
  • The analysis of microsatellite instability in extracolonic gastrointestinal malignancy
    Andrew S. Williams, Weei-Yuarn Huang
    Pathology.2013; 45(6): 540.     CrossRef
Expression of Multidrug Resistance Protein 1 in Human Hepatocellular Carcinoma.
Yun Kyung Kang
Korean J Pathol. 2011;45(3):281-289.
DOI: https://doi.org/10.4132/KoreanJPathol.2011.45.3.281
  • 2,871 View
  • 16 Download
AbstractAbstract PDF
BACKGROUND
Multidrug resistance protein 1 (MDR1) encoded by ATP-binding cassette, sub-family B (Mdr/Tap), member 1 (ABCB1) mediates cross-resistance to antineoplastic drugs, and its expression is related to tumor aggressiveness.
METHODS
MDR1 expression was investigated in 100 hepatocellular carcinomas (HCCs) by immunohistochemical staining. The epigenetic mechanisms underlying ABCB1 transcriptional regulation were investigated in cell lines.
RESULTS
MDR1 was normally localized in the bile canalicular surface of the hepatocytes. Among 100 HCCs, 45 showed canalicular/luminal (CL) staining similar to the normal pattern, another 45 displayed membranous/cytoplasmic (MC) overexpression, and the remaining 10 revealed loss of expression. MC pattern or null staining of HCCs correlated with a higher histological grade and had a poorer prognosis than HCCs with a CL pattern (p<0.05). They also tended to have a poor prognosis by multivariate survival analysis. The ABCB1 promoter was hypomethylated regardless of MDR1 expression or ABCB1 mRNA levels in 10 HCC cell lines. Histone deacetylase inhibitor treatment induced ABCB1 upregulation in 4 cell lines with low or moderate ABCB1 levels.
CONCLUSIONS
Our findings suggest that either an increase or a loss of MDR1 expression may contribute to the poor outcome of HCCs; histone deacetylation may be one of the epigenetic mechanisms directing the ABCB1 expression in HCCs.
Prognostic Implications of the Expression of CXCL16 in Breast Carcinoma.
Dong Youl Choi, Ran Hong, Sung Churl Lim, Keun Hong Kee, Chae Hong Suh, Mija Lee
Korean J Pathol. 2011;45(1):15-20.
DOI: https://doi.org/10.4132/KoreanJPathol.2011.45.1.15
  • 3,514 View
  • 24 Download
  • 1 Citations
AbstractAbstract PDF
BACKGROUND
Of the many prognostic factors for breast cancer, the relationship between an infiltration of inflammatory cells and the prognosis is debatable. Of the chemokines affecting cancer's inflammatory reactions, chemokine (C-X-C motif) ligand 16 (CXCL16) has attracted attention for its prognostic value in many cancers, including colorectal cancer and renal cell carcinoma. But the situation for breast carcinoma is unknown. The aim of this study was to examine the relationship between the prognostic factors and the CXCL16 expression in patients with breast carcinoma.
METHODS
The patients (n=106) diagnosed with invasive ductal cancer of the breast were enrolled. We reviewed the clinicopathological factors of these patients, hematoxylin and eosin stains were prepared and estrogen receptor (ER), human epidermal growth factor receptor 2 (HER2/neu) and CXCL16 immunostaining was performed.
RESULTS
The ER expression was significantly correlated with age and inflammation. A CXCL16 expression was noted in 81.1% of the cases. No association was evident between a CXCL16 expression and any other parameter, including the survival rate. Multivariate analysis did not implicate ER, HER2/neu or CXCL16 as an independent prognostic factor, but the tumor size was independent predictive factor for the patient outcome.
CONCLUSIONS
An inflammatory reaction mediated by CXCL16 is not associated with the prognosis of breast cancer or any clinicopathological factors.

Citations

Citations to this article as recorded by  
  • The emerging role of CXC chemokines and their receptors in cancer
    Victoria Vinader, Kamyar Afarinkia
    Future Medicinal Chemistry.2012; 4(7): 853.     CrossRef
Expressions of the Tumor Associated Proteins and Their Correlation with the Pathologic Features in Childhood Hepatoblastoma.
Han Seong Kim, Hyo Seop Ahn, Kwi Won Park, Ja June Jang
Korean J Pathol. 1997;31(6):538-545.
  • 1,240 View
  • 10 Download
AbstractAbstract PDF
Hepatoblastoma is a rare malignant liver tumor found in children. Its biological characteristics and prognostic factors have not been well known. We investigated 29 cases of hepatoblastoma, registered in university hospitals in Seoul from 1984 to 1996. By the immunohistochemical method, p53, Waf-1 (p21), bcl-2, heat shock protein 70 (hsp70), c-jun, transforming growth factor-alpha (TGF-alpha) expressions were studied. Those data were compared with clinico-pathologic features; age, sex, tumor size, tumor stage and histologic subtypes. Expression of p53 and bcl-2 were each observed separately in single cases. Expression of c-jun was more frequently noted in patients at higher stages. Expression of TGF-alpha decreased in the order of pure fetal, mixed, embryonal and small cell anaplastic subtypes. Cumulative survival rate was lower in females than in males and in patients with a higher tumor stage. According to histologic subtypes, survival rates decreased in the order of pure fetal, mixed, embryonal and small cell anaplastic subtypes. Survival rate was lower in patients with c-jun expression. Group of TGF-alpha labelling index under 19 showed a lower survival rate than that over 19. In conclusion, we found that tumor associated proteins, c-jun and TGF-alpha, are closely related to the prognosis of hepatoblastoma but p53 and bcl-2 may not be related to it.
Prognostic Significance of PCNA Index and AgNORs Score in Transitional Cell Carcinoma of the Renal Pelvis.
Wan Seop Kim, Seung Sam Paik, Nam Hoon Kim, Moon Hyang Park, Jung Dal Lee
Korean J Pathol. 1998;32(7):521-530.
  • 1,339 View
  • 10 Download
AbstractAbstract
Proliferative activity of a malignant tumor is known to reflect its biological aggressiveness. Proliferating cell nuclear antigen (PCNA) is a marker of cellular proliferation, and silver-stained nucleolar organizer regions (AgNORs) have been shown to correlate with ploidy and proliferative activity of cells. In transitional cell carcinoma of the renal pelvis, the prognostic value of these markers has not been well defined. We studied PCNA expression and the AgNORs count in 22 transitional cell carcinoma of the renal pelvis to assess their prognostic significance compared with their cumulative survival rate, the stage of disease and histopathologic features of the tumors. An immunohistochemical method and a standard colloidal silver staining were used. The mean percentage of PCNA positivity (PCNA index) and the mean number of AgNORs per nucleus (AgNORs score) were determined. In a multivariable analysis, PCNA indexes were significantly associated with tumor stage (p=0.024), whereas AgNORs scores were not significantly associated with the stage or histopatholgic features of the tumors. Histologic grade was correlated to disease stage at a significant level (p=0.000). But there was a trend of low tumor PCNA-indices or AgNORs counts with survival advantage for patients, but this did not reach statistical significance. The results suggest that the fraction of PCNA positive nuclei would be useful for investigating the malignant potential of renal pelvic cancers, although their clinical use as markers of biologic behavior may be limited.

JPTM : Journal of Pathology and Translational Medicine